Neo Ethics Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 06-07-2024
- Paid Up Capital ₹ 1.84 M
as on 06-07-2024
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.24 M
as on 06-07-2024
- Revenue 0.74%
(FY 2021)
- Profit 38.97%
(FY 2021)
- Ebitda -22.31%
(FY 2021)
- Net Worth 146.46%
(FY 2021)
- Total Assets 8.64%
(FY 2021)
About Neo Ethics Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.84 M.
The company has closed loans amounting to ₹0.24 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nagasamy Krishnamurthy and Saroja Subramaniam serve as directors at the Company.
- CIN/LLPIN
U24231TN1990PTC018549
- Company No.
018549
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 1990
- Date of AGM
02 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neo Ethics Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagasamy Krishnamurthy  | Director | 27-Jun-2018 | Current |
| Saroja Subramaniam | Director | 15-Jul-1994 | Current |
Financial Performance of Neo Ethics Pharmaceuticals.
Neo Ethics Pharmaceuticals Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 0.74% increase. The company also saw a substantial improvement in profitability, with a 38.97% increase in profit. The company's net worth Soared by an impressive increase of 146.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neo Ethics Pharmaceuticals?
In 2019, Neo Ethics Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ve Leathers India Private LimitedActive 31 years 5 monthsNagasamy Krishnamurthy and Saroja Subramaniam are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Tamilnadu Industrial Investment Corp. Ltd. Creation Date: 12 May 1993 | ₹0.24 M | Satisfied |
How Many Employees Work at Neo Ethics Pharmaceuticals?
Unlock and access historical data on people associated with Neo Ethics Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neo Ethics Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neo Ethics Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
